Sodium channel protein type 7 subunit alpha

Description:

Description
  • Accession: Q01118
  • Swissprot: SCN7A_HUMAN
  • Organism: Homo sapiens
  • Gene: SCN7A
  • Target class: Ion channel

Drug Relations:

benzocaine
A surface anesthetic that acts by preventing transmission of impulses along NERVE FIBERS and at NERVE ENDINGS. Bioactivity details MOA
eslicarbazepine acetate
Eslicarbazepine acetate is extensively converted to eslicarbazepine, which is considered to be responsible for therapeutic effects in humans. The precise mechanism(s) by which eslicarbazepine exerts anticonvulsant activity is unknown but is thought to involve inhibition of voltage-gated sodium channels. Bioactivity details MOA
ethotoin
Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread of seizure activity rather than to abolish the primary focus of seizure discharges. Bioactivity details MOA
mephenytoin
An anticonvulsant effective in tonic-clonic epilepsy (EPILEPSY, TONIC-CLONIC). It may cause blood dyscrasias. Bioactivity details MOA
phenazopyridine
A local anesthetic that has been used in urinary tract disorders. Its use is limited by problems with toxicity (primarily blood disorders) and potential carcinogenicity. Bioactivity details MOA
procainamide
A class Ia antiarrhythmic drug that is structurally-related to PROCAINE. Bioactivity details MOA
rufinamide
The precise mechanism(s) by which rufinamide exerts its antiepileptic effect is unknown. The results of in vitro studies suggest that the principal mechanism of action of rufinamide is modulation of the activity of sodium channels and, in particular, prolongation of the inactive state of the channel. Bioactivity details MOA
tocainide
An antiarrhythmic agent which exerts a potential- and frequency-dependent block of SODIUM CHANNELS. Bioactivity details MOA